Direct association of heat shock protein 20 (HSPB6) with phosphoinositide 3-kinase (PI3K) in human hepatocellular carcinoma: Regulation of the PI3K activity

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Matsushima Nishiwaki, Rie ^a   Kumada, Takashi ^b   Nagasawa, Tomoaki ^a   Suzuki, Mariko ^a   Yasuda, Eisuke ^c   Okuda, Seiji ^b   Maeda, Atsuyuki ^b   Kaneoka, Yuji ^b   Toyoda, Hidenori ^b   Kozawa, Osamu ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OGAKI MUNICIPAL HOSPITAL   (Japan)

^c SUZUKA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN 20; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P110; PROTEIN P85; TRANSFORMING GROWTH FACTOR ALPHA;

ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL STIMULATION; CELL STRAIN; CELL STRAIN HUH7; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTES; HSP20 HEAT-SHOCK PROTEINS; HUMANS; LIVER NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84892382494     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078440     Document Type: Article

References (39)

1. Becker J, Craig EA (1994) Heat-shock proteins as molecular chaperones. Eur J Biochem 219: 11-23.
2. Kampinga HH, Hageman J, Vos MJ, Kubota H, Tanguay RM, et al. (2009) Guidelines for the nomenclature of the human heat shock proteins. Cell Stress Chaperones 14: 105-111.
3. Mymrikov EV, Seit-Nebi AS, Gusev NB (2011) Large potentials of small heat shock proteins. Physiol Rev 91: 1123-1159.
4. Shanner L, Morano KA (2007) All in the family: atypical Hsp70 chaperones are conserved modulators of Hsp70 activity. Cell Stress Chaperones 12: 1-8.
5. Kappé G, Franck E, Verschuure P, Boelens WC, Leunissen JAM, et al. (2003) The human genome encodes 10 α-crystallin-related small heat shock proteins: HspB1-10. Cell Stress Chaperones 8: 53-61.
6. Taylor RP, Benjamin IJ (2005) Small heat shock proteins: a new classification scheme in mammals. J Mol Cell Cardiol 38: 433-444.
7. Wang Y, Xu A, Ye J, Kraegen EW, Tse CA, et al. (2001) Alteration in phosphorylaiton of P20 is associated with insulin resistance. Diabetes 50: 1821-1827.
8. Flynn CR, Brophy CM, Furnish EJ, Komalavilas P, Tessier D, et al. (2005) Transduction of phosphorylated heat shock-related protein 20, HSP20, prevents vasospasm of human umbilical artery smooth muscle. J Appl Physiol 98: 1836-1845.
9. Komalavilas P, Penn RB, Flynn CR, Thresher J, Lopes LB, et al. (2008) The small heat shock-related protein, HSP20, is a cAMP-dependent protein kinase substrate that is involved in airway smooth muscle relaxation. Am J Physiol Lung Cell Mol Physiol 294: L69-L78.
10. Fan G-C, Kranias EG (2011) Small heat shock protein 20 (HspB6) in cardiac hypertrophy and failure. J Mol Cell Cardiol 51: 574-577.
11. Matsuno H, Kozawa O, Niwa M, Usui A, Ito H, et al. (1998) A heat shockrelated protein, p20, plays an inhibitory role in platelet activation. FEBS Lett 429: 327-329.
12. Kozawa O, Matsuno H, Niwa M, Hatakeyama D, Oiso Y, et al. (2002) HSP20, low-molecular-weight heat shock-related protein, acts extracellularly as a regulator of platelet functions: a novel defense mechanism. Life Sci 72: 113-124.
13. Aravalli RN, Cressman ENK, Steer CJ (2013) Cellular and molecular mechanisms of hepatocellular carcinoma: an update. Arch Toxicol 87: 227-247.
14. Daveau M, Scotte M, François A, Coulouarn C, Ros G, et al. (2003) Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma. Mol Carcinog 36: 130-141.
15. Breuhahn K, Longerich T, Schirmacher P (2006) Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 25: 3787-3800.
16. Cantley LC (2002) The phosphoinositide 3-kinase pathway. Sicience 296: 1655-1657.
17. Song MS, Salmena L, Pandolfi PP (2012) The functions and regulation of the PTEN tumor suppressor. Nar Rev Moll Cell Biol 13: 283-296.
18. Vivanco I, Sawyers CL (2002) The phosphatidylonositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer 2: 489-501.
19. Chen Y, Wang B-C, Xiao Y (2012) PI3K: a potential therapeutic target for cancer. J Cell Physiol 227: 2818-2821.
20. Yu J, Zhang Y, McIlroy J, Rordorf-Nikolic T, Orr GA, et al. (1998) Regulation of the p85/p110 phosphatidylinositol 3′-kinase: stabilization and inhibition of the p110α catalytic subunit by the p85 regulatory subunit. Mol Cell Biol 18: 1379-1387.
21. Zhao L, Vogt PK (2008) Class I PI3K in oncogenic cellular transformation. Oncogene 27: 5486-5496.
22. Taniguchi CM, Winnay J, Kondo T, Bronson RT, Guimaraes AR, et al. (2010) The phosphoinositide 3-kinase regulatory subunit p85α can exert tumor suppressor properties through negative regulation of growth factor signaling. Cancer Res 70: 5305-5315.
23. Noda T, Kumada T, Takai S, Matsushima-Nishiwaki R, Yoshimi N, et al. (2007) Expression levels of heat shock protein 20 decrease in parallel with tumor progression in patients with hepatocellular carcinoma. Oncol Rep 17: 1309-1314.
24. Matsushima-Nishiwaki R, Adachi S, Yoshioka T, Yasuda E, Yamagishi Y, et al. (2011) Suppression by heat shock protein 20 of hepatocellular carcinoma cell proliferation via inhibition of the mitogen-activated protein kinases and AKT pathways. J Cell Biochem 112: 3430-3439.
25. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
26. Biéche I, Onody P, Tozlu S, Driouch K, Vidaud M, et al. (2003) Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer 106: 758-765.
27. Fan G-C, Zhou X, Wang X, Song G, Qian J, et al. (2008) Heat shock protein 20 interacting with phosphorylated Akt reduces doxorubicin-triggered oxidative stress and cardiotoxicity. Circ Res 103: 1270-1279.
28. Su B, Karin M (1996) Mitogen-activated protein kinase cascades and regulation of gene expression. Curr Opin Immunol 8: 402-411.
29. Viahos CJ, Matter WF, Hui KY, Brown RF (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran- 4-one (LY294002). J Biol Chem 269: 5241-5248.
30. Brophy CM, Lamb S, Graham A (1999) The small heat shock-related protein-20 in an actin-associated protein. J Vasc Surg 29: 326-333.
31. Seit-Nebi AS, Gusev NB (2010) Versatility of the small heat shock protein HSPB6 (Hsp20). Cell Stress Chaperones 15: 233-236.
32. Wang X, Zhao T, Huang W, Wang T, Qian J et al. (2009) Hsp20-engineered mesenchymal stem cells are resistant to oxidative stress via enhanced activation of Akt and increased secretion of growth factors. Stem Cells 27: 3021-3031.
33. Ueki K, Algenstaedt P, Mauvais-Jarvis F, Kahn R (2000) Positive and negative regulation of phosphoinisitide 3-kinase dependent signaling pathways by three different gene products of the p85α regulatory subunit. Mol Cell Biol 20: 8035-8046.
34. Courtney KD, Corcoran RB, Engelman JA (2010) The PI3K pathway as drug target in human cancer. J Clin Oncol 28: 1075-1083.
35. Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, et al. (2009) Somatic mutations in p85α promote tumorigenesis through class IA PI3K activation. Cancer Cell 16: 463-474.
36. Vogt PK (2011) PI3K p110β: More tightly controlled or constitutively active? Mol Cell 41: 499-501.
37. Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC et al. (2012) A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 18: 4173-4182.
38. Rodriguez-Viclana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, et al. (1994) Phosphhatidylinositol-3-OH kinase as a direct target of Ras. Nature 370: 527-532.
39. Tanaka K, Fujimoto Y, Suzuki M, Suzuki Y, Ohtake T, et al. (2001) Pi3-kinase p85α is a target molecule of proline-rich antimicrobial peptide to suppress proliferation of ras-transformed cells. Jpn J Cancer Res 92: 959-967.